Benjamin Wolozin, MD, PhD, associate professor of pharmacology and neurology at BUSM,
BUSM is home to one of the largest and most rapidly growing research programs among U.S. medical schools. There are currently more than 640 funded research programs that total more than $175 million in support and provide an exceptional environment for students interested in basic science, clinical investigation, or public health- and health services-oriented research.
The National Emerging Infectious Diseases Laboratories (NEIDL) is the next step in advancing public health and biomedical research. The biocontainment laboratory has been developed in partnership with the National Institute of Allergy and Infectious Diseases. Its mission is to develop diagnostic drugs, vaccines, and treatments to prevent and cure life-threatening infectious diseases.
The Framingham Heart Study, which has been administered by BUSM faculty in cooperation with the National Heart, Lung and Blood Institute since 1971, was initiated in 1948 to identify factors contributing to cardiovascular disease, principally heart attack and stroke. For the past 60 years, the study participants have returned every two years to undergo a detailed medical history, physical examination, and laboratory tests, providing BUSM and other researchers a wealth of information on cardiovascular disease and a host of factors that affect physical and cognitive health. Two additional generations—children and grandchildren of the original group—have been added to the study. The principal investigators and the project directors of the Framingham Heart Study are BUSM faculty.